Table 2.
Rates of VMA resolution and FTMH closure in the four studies and the integrated dataset
|
| ||||
| MIVI-TRUST* n (%) | OASIS n (%) | ORBIT n (%) | Integrated n (%) | |
| Number of patients | 106 | 50 | 118 | 274 |
| VMA resolution | 53 (50.0) | 27 (54.0) | 74 (62.7) | 154 (56.2) |
| FTMH closure | 43 (40.6) | 15 (30.0) | 38 (32.2) | 96 (35.0) |
| VMA resolution: Yes FTMH closure: Yes | 24 (22.6) | 8 (16.0) | 30 (32.2) | 62 (22.6) |
| VMA resolution: Yes FTMH closure: No | 29 (27.4) | 19 (38.0) | 44 (37.3) | 92 (33.6) |
| VMA resolution: No FTMH closure: Yes | 19 (17.9) | 7 (14.3) | 8 (6.8) | 34 (12.4) |
| VMA resolution: No FTMH closure: No | 24 (22.6) | 8 (16.0) | 30 (25.4) | 86 (31.4) |
| *MIVI-TRUST consisted of two phase 3 clinical trials (NCT00781859 and NCT00798317) FTMH, full-thickness macular hole; VMA, vitreomacular adhesion | ||||